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ABSTRACT 20 
Background 21 
In Parkinson’s disease (PD), impulse control disorders (ICDs) develop as side-effect 22 
of dopaminergic replacement therapy (DRT). One hypothesis is that DRT overdoses 23 
less-severely affected dopamine-modulated circuits on which cognition, affect and 24 
motivation depend. However, cognitive, affective and motivational correlates of ICD 25 
in medicated PD patients are debated. Here, we systematically reviewed and meta-26 
analyzed the evidence for an association between ICD in PD and cognitive, affective 27 
and motivational abnormalities. 28 
Methods 29 
A systematic review and meta-analysis was performed on PubMed, Science Direct, 30 
ISI Web of Science, Cochrane, EBSCO for studies published between 1-1-2000 and 31 
8-3-2017 comparing cognitive, affective and motivational measures in PD patients 32 
with ICD (ICD+) vs. those without ICD (ICD-). Exclusion criteria were conditions 33 
other than PD, substance and/or alcohol abuse, dementia, drug naïve patients, 34 
cognition assessed by self-report tools. Standardized mean difference (SMD) was 35 
used, and random-effect model applied. 36 
Results 37 
10,200 studies were screened (title, abstract), 79 full-texts were assessed, and 25 were 38 
included (ICD+: 625 patients; ICD-: 938). Compared to ICD-, ICD+ showed worse 39 
performance reward-related decision-making (0.42 [0.02, 0.82], p=0.04) and set-40 
shifting tasks (SMD=-0.49 [95% CI -0.78, -0.21], p=0.0008). ICD in PD was also 41 
related to higher self-reported rate of depression (0.35 [0.16, 0.54], p=0.0004), 42 
anxiety (0.43 [0.18, 0.68], p=0.0007), anhedonia (0.26 [0.01, 0.50], p=0.04), and 43 
impulsivity (0.79 [0.50, 1.09], p<0.00001). Heterogeneity was low to moderate, 44 
except for depression (I2=61%) and anxiety (I2=58%). 45 
Conclusions 46 
ICD in PD is associated with worse set-shifting and reward-related decision-making, 47 
and increased depression, anxiety, anhedonia and impulsivity. This is an important 48 
area for further studies as ICDs have negative impact on the quality of life of patients 49 
and their caregivers.50 
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INTRODUCTION 51 
Impulse control disorders (ICDs), such as pathological gambling, hypersexuality, 52 
binge-eating and compulsive shopping, can occur in over 13% of medicated 53 
Parkinson’s disease (PD) patients [1]. Although ICDs are recognized as side-effect of 54 
dopamine replacement therapy (DRT), mainly D2 dopamine agonists and levodopa, 55 
their pathophysiology is unclear. 56 
It has been hypothesized that, in vulnerable individuals, DRT used to restore 57 
dopamine levels in nigrostriatal circuitry may overstimulate the less severely affected 58 
mesocorticolimbic circuitry [2]. Mesocorticolimbic overstimulation may disrupt 59 
prefrontal-dependent executive function, affect and motivation and thus increase 60 
vulnerability to ICD. According to this view, in medicated PD patients, we should 61 
expect a correlation between ICD and cognitive, affective and motivational factors. 62 
However, data in the literature are inconclusive.  63 
Studies on cognition, affective processing and motivation conducted in small cohorts 64 
of PD patients with and without ICD (i.e., n: 17-155 patients) yielded inconsistent 65 
findings with respect to frontal cognitive abilities in PD patients with ICD. Some 66 
studies reported worse performance in executive function, including set-shifting [3–67 
7], working memory [8], concept formation and reasoning [5,7], and reward-related 68 
decision-making [9–15] in PD with ICD (ICD+) compared to PD without ICD (ICD-69 
). Conversely, other studies found similar performances for inhibition [9,16–18], set-70 
shifting [19,20], working memory [3,11,17,21,22], and reward-related decision-71 
making [16,17,20,23]. Finally, a single study reported better executive functions in 72 
ICD+ [24]. Reports on affective factors are also inconclusive, as self-reported 73 
depression and anxiety were sometimes found to be associated with ICD 74 
[18,20,21,25–28], and sometimes not [3–6,17,19,22,29–31]. However, motivational 75 
factors such as self-reported apathy [11,21,27,28], anhedonia [27,32], and impulsivity 76 
[17,20–22,32] appeared to be elevated in ICD+ vs. ICD-. 77 
A recent meta-analysis identified several cognitive subdomains (i.e., concept 78 
formation, set-shifting, reward-related decision-making, and visuospatial abilities) to 79 
be worse in ICD+ vs. ICD- [33], but it included a mixed sample of medicated and 80 
drug naïve patients that did not allow to explore the relationship between cognitive 81 
disturbances, DRT and ICD. Second, it included patients with comorbidities for 82 
substance abuse and/or dementia, two factors that could be independently associated 83 
with cognitive changes. Finally, the relationship between cognition-emotion and 84 
cognition-motivation, critical to understanding the broader context in which ICDs 85 
develop, was not explored in the previous meta-analysis [34].  86 
To reconcile discordant findings in the literature about cognitive, affective and 87 
motivational correlates of ICD in medicated PD patients, a systematic review and 88 
meta-analysis was conducted. Moreover, this work is meant to address the issues of a 89 
previous meta-analysis and to offer new information on this topic. To this aim, we 90 
applied stricter inclusion and exclusion criteria, by including only studies on PD 91 
patients under DRT at the time of assessment and free from co-morbid substance 92 
abuse and/or dementia. Moreover, we included studies with affective and 93 
motivational measures, so that any cognitive change could be interpreted within the 94 
broader context of cognition-emotion and cognition-motivation relationships [34]. A 95 
clear understanding of cognitive, affective and motivational changes in ICD may 96 
indirectly increase our understanding of ICD pathophysiology and in turn its 97 
management. 98 
 99 
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METHODS 100 
 101 
Study design, participants and comparators 102 
A systematic review and meta-analysis were performed to identify cognitive, affective 103 
and motivational factors associated with ICD in PD under DRT (ICD+). The 104 
comparator group was patients with PD but no ICD (ICD-).  105 
 106 
Search strategy and selection criteria 107 
On June 26th 2016, PubMed, Science Direct, ISI Web of Science, Cochrane, EBSCO 108 
were searched for peer-reviewed papers in English, Italian and Spanish published 109 
since January 2000, when the first report of ICD development after dopaminergic 110 
medication initiation was reported [35]. The systematic review was further updated on 111 
March 8th 2017. 112 
Studies were identified using the following string [36] in PubMed: “(Parkinson’s 113 
disease) AND (impulse control disorders OR impulsivity OR cognition OR decision-114 
making)”. The search strategy for the other databases included (Parkinson’s disease) 115 
AND (impulse control disorders), then (Parkinson’s disease) AND (impulsivity), then 116 
(Parkinson’s disease) AND (cognition), and (Parkinson’s disease) AND (decision-117 
making). A total of 40,672 papers were identified. After exclusion of duplicates, 118 
10,200 papers were title and abstract screened. 119 
Studies were included if: a) PD patients were under DRT; b) ICD assessment was 120 
performed in a reliable manner with the Questionnaire for Impulsive-Compulsive 121 
Disorders in Parkinson's Disease (QUIP), the QUIP rating scale (QUIP-rs), the 122 
Minnesota Impulse Disorders Interview, clinical interview based on diagnostic 123 
criteria, or a combination of these; c) performances of PD patients with ICD (ICD+) 124 
were compared with those with PD but no history of ICD (ICD-); d) cognitive, 125 
affective and/or motivational measures were reported. A further inclusion criterion 126 
was independence of samples. Only baseline data for prospective studies and the 127 
study with the largest sample for multiple studies published by the same author(s) 128 
were included. 129 
We excluded reviews, case studies, commentaries, letters, abstracts and dissertations, 130 
and postal surveys. Studies including drug naïve PD patients were also excluded since 131 
we were interested in ICD developed as a DRT side-effect. Studies in which PD 132 
patients underwent non-pharmacological treatments such as deep brain stimulation 133 
(DBS) were excluded. This criterion was based on controversial reports of either ICD 134 
amelioration or ICD appearance after DBS [37], and the notion that DBS may worsen 135 
some cognitive outcomes [38]. Studies including participants with dementia and 136 
drug/alcohol abuse were excluded, as these conditions might be independently 137 
associated with cognitive and neuropsychiatric changes.  Other exclusion criteria 138 
were: cognition assessed by self-report measures or by general screening tools (e.g., 139 
Mini-Mental State Examination) because of their limited specificity and sensitivity 140 
[39]. Studies focusing on dopamine dysregulation syndrome and/or punding only 141 
were not included since these conditions are considered different from ICD, as they 142 
are more common in patients with advanced PD, cognitive impairment and dementia 143 
[40]. However, screening questionnaires (e.g., QUIP, QUIP-rs) include dopamine 144 
dysregulation syndrome and punding, and some ICD+ patients we included may have 145 
had these conditions too, in addition to ICD. Finally, to ensure that the ICD- group 146 
included patients without any type of ICD, studies not assessing all ICD types (e.g., 147 
using only the South Oaks Gambling Screen) were excluded.  148 
 149 
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Data extraction 150 
Following exclusion of duplicate and irrelevant articles through title and abstract 151 
screening, 79 papers were included for full-text evaluation. Reference lists of these 152 
studies were manually searched to identify additional relevant articles, and two papers 153 
were included at this stage. 154 
Two reviewers (AM, DDL) independently screened titles and abstracts using Rayyan 155 
software [41], and three reviewers (AM, DDL, ST) independently evaluated papers 156 
selected for full-text examination. Disagreements were resolved through discussions. 157 
Disagreement concerned one paper [42] over the 75 selected for full-text examination 158 
(inter-rater agreement: 99.21%). Twenty-five articles were included for quantitative 159 
analysis (Figure 1). 160 
 161 
-- Figure 1 near here -- 162 
 163 
Corresponding authors of five studies were contacted for exact data. Means and 164 
standard deviations were obtained for two studies, which reported median and 165 
interquartile ranges [20,25], according to a proposed formula [43]. Two reviewers 166 
(AM, DDL) independently extracted the following data: sample size, age at 167 
evaluation, age at PD onset, PD duration, education (years), Hoehn and Yahr (H&Y) 168 
stage, Unified Parkinson’s Disease Rating Scale motor section (UPDRS-III) ON-169 
medication, depression, antidepressants use, antipsychotics use, total levodopa 170 
equivalent daily dose (LEDD, mg), levodopa LEDD, dopamine agonist LEDD, 171 
outcomes, ICD screening tool, ICD type, and statistics. 172 
Primary outcomes were cognitive, affective and motivational scores. Cognitive tests 173 
were categorized on the basis of the main cognitive process involved [44]. The 174 
categories were ‘memory’(short-term verbal and visuospatial memory, long-term 175 
verbal and visuospatial memory); ‘working memory’; ‘attention’; ‘executive function’ 176 
(concept formation and reasoning, concept formation sort and shift, set-shifting, 177 
inhibition, cognitive flexibility, reward-related decision-making); ‘visuospatial 178 
abilities’; ‘language’; ‘apraxia’; ’novelty seeking’; ‘incentive salience’ and ‘data 179 
gathering’. Concept formation and reasoning relates to the development of ideas 180 
based on the common properties of objects, events, or qualities using abstraction and 181 
generalization processes whilst concept formation sort and shift requires to form a 182 
sorting principles and apply it (sort), and then abandon it and switch to a different 183 
principle (shift) [44]. 184 
Affective and motivational measures were categorized as depression, anxiety, 185 
anhedonia, apathy and impulsivity. 186 
Cognitive processes assessed in a single study (i.e., novelty seeking, incentive 187 
salience, data gathering, apraxia) were not included in the meta-analysis. When a 188 
study reported multiple measures for the same outcome, the most relevant one was 189 
chosen by two reviewers with expertise on neuropsychological assessment (AM, 190 
DDL). 191 
 192 
Data analysis 193 
Data were analyzed using ReviewManager v5.3 [45]. Effect size was estimated as 194 
standardized mean difference (SMD), which is comparable to Hedges’ adjusted g 195 
value. Effect sizes of 0.2, 0.5 and 0.8 or more are considered as small, moderate and 196 
large, respectively [46]. Cochran’s Q (χ2) was used to test heterogeneity between 197 
studies. The degree of heterogeneity was quantified by I2, which values range 198 
between 0% and 100%. I2 percentages of 25, 50, 75 are considered as low, moderate 199 
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and high, respectively [47]. Random-effect model was applied, as patients differ in 200 
clinical (e.g., UPDRS-III ON medication range: 10.9 - 36.7) and demographic 201 
characteristics (e.g., age range: 54.6 – 71.4), therefore the true effect may vary from 202 
study to study. In contrast to fixed-effect models, random-effect models consider both 203 
within and between study variances. As heterogeneity was moderate to high for some 204 
outcomes (i.e., working memory, depression, anxiety, and apathy), the consequences 205 
of applying a fixed-effect model, which does not consider between studies variance, 206 
may result in type I error rate inflation Conversely, if random-effect models are 207 
applied with effect sizes that vary only due to sampling error as when heterogeneity is 208 
low (i.e., short-term visuospatial memory, attention, concept formation reasoning, 209 
anhedonia) to fixed effects data, the consequences are less dramatic (e.g., using 210 
Hedges’ method, the additional between-study effect size variance used in the random 211 
effect method becomes zero when sample effect sizes are homogeneous, yielding the 212 
same result as the fixed effect method) [48]. Moreover, following this approach, 213 
studies were not excluded because of their small sample size, because in random-214 
effect models effect sizes are weighed by their variance, which is higher in smaller 215 
studies. 216 
Two authors independently explored funnel plots for publication bias (AM, DDL), 217 
and incongruences were resolved by discussion with two other authors (ST, JAG). 218 
Funnel plots of outcomes with less than ten studies were not inspected since the 219 
power is too low to discriminate publication bias’s asymmetry from chance [49]. 220 
Blinding of assessors (performance bias) and incomplete data outcome (attrition bias) 221 
were independently assessed for each study as “low risk”, “high risk” or “unclear” by 222 
two reviewers (AM, DDL) following Cochrane Collaboration recommendations. 223 
Sensitivity analysis was performed by excluding one study at time and verifying its 224 
impact on the overall effect size. Sensitivity analysis was not performed for outcomes 225 
with two studies. Moderator analysis via meta-regression was performed using SPSS 226 
version 21.0 [50]. We tested the hypothesis that variation among studies in effect size 227 
was associated with differences in age, years of education, disease duration, UPDRS-228 
III score, H&Y score, total LEDD, levodopa LEDD, and dopamine agonist LEDD. As 229 
suggested by Borenstein [51], moderator analysis was conducted only for outcomes in 230 
which there were at least ten studies to one covariate. 231 
 232 
RESULTS 233 
After removal of duplicates, 10,200 records were screened by title and abstract, 79 234 
full-text articles were assessed for eligibility, and 54 were excluded (Figure 1). 235 
Twenty-five studies were included in the meta-analysis (Table 1). 236 
 237 
-- Table 1 near here -- 238 
 239 
Four studies investigated cognitive performance without affective and motivational 240 
outcomes [8,9,16,23], seventeen studies included both cognitive, affective and 241 
motivational outcomes [3–6,10,11,17–22,27,30–32,50], and four studies included 242 
affective and motivational data only [25,26,28,29]. Three studies divided ICD+ in two 243 
groups: PD patients with pathological gambling and those with ICD other than 244 
pathological gambling [16,27,32], and one study divided the ICD+ in multiple and 245 
single ICD groups [26]. As the comparison between ICD subtypes was not relevant in 246 
our meta-analysis, sub-groups were merged by calculating the pooled means and 247 
standard deviations. In one study [6] ICD+ group was divided in pathological 248 
gambling, binge-eating, hypersexuality and multiple ICD sub-groups. Since seven PD 249 
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patients belonging to either the pathological gambling or the binge-eating sub-groups 250 
developed ICD before DRT initiation, only data from hypersexuality and multiple 251 
ICD sub-groups were extracted and merged as described above. Six studies focused 252 
on neuroimaging outcomes but also provided affective [26] and cognitive measures 253 
[3–5,23,30]. One study retrospectively investigated persistent, remitting, and new-254 
onset ICD before and after subthalamic nucleus DBS (STN-DBS) [42]. For this study, 255 
only pre-STN-DBS data of persistent and never experienced ICD were included in the 256 
meta-analysis. Despite the fact that dementia was not explicitly excluded [42], data 257 
were included because STN-DBS is performed in non-demented patients only. 258 
The meta-analysis includes 1563 subjects. The ICD+ group was composed of 625 259 
patients (mean age range: 54.6–68.7 years; mean PD duration: 2.4–14.3 years; mean 260 
H&Y: 1.3–2.8; mean UPDRS-III score ON medication: 10.9–36.7). The ICD- group 261 
included 938 patients (mean age: 55–71.4 years; mean PD duration: 2.3–13.1 years; 262 
mean H&Y stage: 1.4–2.5; mean UPDRS-III score ON medication: 11.7–32.3). 263 
Fourteen meta-analyses were performed to compare cognitive outcomes and five to 264 
compare affective and motivational measures in ICD+ compared to ICD- groups. 265 
The following cognitive outcomes were explored: short-term verbal and visuospatial 266 
memory, long-term verbal and visuospatial memory, working memory, attention, set-267 
shifting, concept formation (reasoning, sort and shift), inhibition, cognitive flexibility, 268 
reward-related decision-making, visuospatial abilities, and language (Table 2). 269 
 270 
--Table 2 near here -- 271 
 272 
ICD+ showed worse performance in set-shifting (SMD=-0.49; 95% CI: -0.78, -0.21; 273 
Z=3.37; p=0.0008) and reward-related decision-making (SMD=0.42; 95% CI: 0.02, 274 
0.82; Z=2.05; p=0.04). The heterogeneity was low-to-moderate for set-shifting 275 
(χ2=9.32, p=0.16, I2=36%) and moderate for reward-related decision-making 276 
(χ2=15.50, p=0.03, I2=55%). Effect sizes for the other cognitive outcomes did not 277 
differ significantly between groups. Heterogeneity was low for short-term 278 
visuospatial memory, attention, concept formation (reasoning), moderate for cognitive 279 
flexibility, concept formation (sort and shift), and language, high for short-term verbal 280 
memory, long-term verbal memory, long-term visuospatial memory, visuospatial 281 
abilities, and inhibition, moderate-to-high for working memory (Figures 2-6). 282 
 283 
--Figures 2-6 near here -- 284 
 285 
The following self-reported affective and behavior outcomes were explored: 286 
depression, anxiety, anhedonia, apathy and impulsivity. ICD+ showed increased 287 
depression (SMD=0.35; 95% CI: 0.16, 0.54; Z=3.54; p=0.0004), anxiety (SMD=0.43; 288 
95% CI: 0.18, 0.68; Z=3.39; p=0.0007), anhedonia (SMD=0.26; 95% CI: 0.01, 0.50; 289 
Z=2.01; p=0.04), and impulsivity (SMD=0.79; 95% CI: 0.50, 1.09; Z=5.26; 290 
p<0.00001), but comparable apathy symptoms (Figure 7). Heterogeneity was low for 291 
anhedonia (χ2=0.01, p=0.94, I2=0%), moderate for impulsivity (χ2=8.89, p=0.11, 292 
I2=44%), and moderate-to-high for depression (χ2=51.42, p=0.0001, I2=61%), anxiety 293 
(χ2=21.27, p=0.01, I2=58%), and apathy (χ2=9.09, p=0.03, I2=67%; Figure 7). Results 294 
of the meta-analyses are summarized in Table 3. 295 
 296 
-- Figure 7 and Table 3 near here -- 297 
 298 
Risk of bias 299 
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Visual exploration of funnel plots did not suggest possible publication bias for short-300 
term verbal memory, inhibition, cognitive flexibility, depression, and anxiety that 301 
were the only outcomes with at least ten studies (Figure 8). 302 
Risk of performance bias was unclear with only 2/25 studies indicating assessors 303 
blinding procedures.  304 
Attrition bias was low, with 4/25 studies with missing data.  305 
 306 
--Figure 8 near here-- 307 
 308 
Sensitivity analysis and moderator analysis 309 
Sensitivity analysis showed that after removing Pontieri et al [27], the overall effect 310 
size of long-term visuospatial memory became significant (SMD=-0.44; 95% CI: -311 
0.75, -0.13; Z=2.81; p=0.005) and the heterogeneity changed from high (χ2=6.64, 312 
p=0.04, I2=70%) to low (χ2= 0.62, p=0.43, I2=0%). After removing Biundo et al [3], 313 
the overall effect size of working memory became significant (SMD=-0.32; 95% CI: -314 
0.63, -0.01; Z=2.05; p=0.04) and the heterogeneity changed from high (χ2=14.73, 315 
p=0.02, I2=59%) to moderate (χ2=8.41, p=0.13, I2=41%). The overall effect size of 316 
attention became significant after removing Merola et al [42] (SMD=-0.27; 95% CI: -317 
0.50, -0.04; Z=2.29; p=0.02), but heterogeneity remained low. The overall effect size 318 
of inhibition became significant after removing Biundo et al [4] (SMD=-0.34; 95% 319 
CI: -0.65, -0.03; Z=2.18; p=0.03) and heterogeneity changed from high to moderate-320 
to-high (χ2=24.18, p=0.004, I2=63%). The overall effect size of reward-related 321 
decision-making lost significance after removing Bentivoglio et al [17] (SMD=0.42; 322 
95% CI: -0.05, 0.89; Z=1.75; p=0.08), Housden et al [11] (SMD=0.36; 95% CI: -0.08, 323 
0.81; Z=1.59; p=0.11), Piray et al [22] (SMD=0.35; 95% CI: -0.08, 0.78; Z=1.58; 324 
p=0.11), and Rossi et al [10] (SMD=0.29; 95% CI: -0.03, 0.61; Z=1.78; p=0.07). 325 
After removing Rossi et al [10], heterogeneity changed from moderate (χ2=15.50, 326 
p=0.03, I2=55%) to low (χ2=8.27, p=0.22, I2=27%). Including or excluding the other 327 
studies did not change heterogeneity. The overall effect size of apathy became 328 
significant after removing Pontieri et al [27] (SMD=0.60; 95% CI: 0.25, 0.95; Z=3.38; 329 
p=0.0007) and heterogeneity changed from high (χ2=9.09, p=0.03, I2=67%) to low 330 
(χ2=2.07, p=0.35, I2=4%).  331 
Moderator analysis was performed for short-term verbal memory, inhibition, 332 
cognitive flexibility, and depression, which were the only outcomes that included at 333 
least ten studies each [51]. Anxiety did not undergo moderator analysis, because none 334 
of the covariates of interest were assessed in at least ten studies. Moderator analysis 335 
showed no effect of age, education, PD duration, H&Y, UPDRS-III, and total LEDD, 336 
levodopa LEDD, dopamine agonist LEDD on short-term verbal memory, inhibition, 337 
cognitive flexibility, and depression (Table 4). 338 
 339 
-- Table 4 near here -- 340 
 341 
DISCUSSION 342 
The primary aim of this meta-analysis of 25 studies was to describe the pattern of 
343 
cognitive function in DRT-medicated ICD+ compared to ICD-. A stricter set of 
344 
inclusion criteria was applied than used previously [33], to achieve a more 
345 
homogenous ICD+ group, and a better understanding of the relationship between ICD 
346 
and cognition in medicated PD. A secondary aim was to examine affective and 
347 
motivational correlates of ICD, as emotion-cognition and motivation-cognition 
348 
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relationships are receiving increasing attention to understand psychopathology and 
349 
improve pharmacological and psychological treatments [34]. 
350 
Our findings suggest ICD to be associated with worse performance on a set of 351 
executive function measures assessing set-shifting (Trail Making Test part B, and B-352 
A) and reward-related decision-making (Iowa Gambling Task, Monetary Risk Task, 353 
Kirby Delay Discounting Questionnaire), with relative sparing of other executive 354 
tasks that assess concept formation and reasoning (Raven’s progressive matrices 355 
standard and colored versions), concept formation sort and shift (Wisconsin card 356 
sorting test standard and modified versions), inhibition (Stroop, Stop Signal Task, 357 
Go/no-Go), and cognitive flexibility (phonological fluency), as well as memory, 358 
working memory, attention, visuospatial abilities, and language.  359 
Set-shifting and reward-related decision-making abilities are important determinants 
360 
of advantageous behavior, serving to translate goals into action planning, as well as 
361 
monitoring response and errors [52].  
362 
Structural and functional neuroimaging outcomes were not included in this meta-
363 
analysis, but neuroanatomical findings in patients with abnormalities in set-shifting 
364 
and reward-related decision-making may help speculate on brain areas that may 
365 
undergo DRT overdose in PD.  Lesion-symptom mapping studies suggest reward-
366 
related decision-making to rely upon an anatomical network composed of the 
367 
ventromedial, orbitofrontal and frontopolar cortices. Set-shifting, which is one of the 
368 
processes underlying cognitive control, depends on rostral anterior cingulate cortex 
369 
functioning [52]. These brain areas form part of the mesocorticolimbic system that, in 
370 
the early stages of PD, undergo less dopaminergic damage than the dorsal striatal 
371 
pathways. 
372 
According to the ‘overdose hypothesis’, the DRT amount required to control motor 
373 
symptoms in PD has the potential to move the same patient away from the optimum 
374 
for certain cognitive functions [53]. The relationship between the efficiency of 
375 
neuronal activity and the state of dopaminergic modulation is represented by a 
376 
Yerkes-Dodson inverted U-shaped curve with cognitive functions declining with 
377 
deviation away from optimum dopamine levels, indicated by the centre of the curve 
378 
[2]. Extrapolating this model to set-shifting and reward-related decision-making 
379 
implies that DRT has the capacity to both improve and impair these executive 
380 
functions depending on baseline dopamine levels in the underlying neural circuitry. 
381 
For patients with low baseline dopamine levels in the mesocorticolimbic system, DRT 
382 
may optimize activity as supported by improved set-shifting and reward-related 
383 
decision-making when assessed in an optimally medicated state compared to the same 
384 
patients assessed following DRT withdrawal [54,55]. By the same token, if patients 
385 
start out with higher mesocorticolimbic baseline levels of dopamine, DRT causes 
386 
dopamine over-activity in the mesocorticolimbic system. This view is consistent with 
387 
evidence that dopamine agonists increase frontal cortex blood flow [56], and enhance 
388 
reward-related risk-taking behavior in ICD+ compared to ICD- [57]. 
389 
A recent meta-analysis of case-control studies on the prevalence of ICD in PD 
390 
provides indirect evidence of dopaminergic over-activity, as being medicated for PD 
391 
and disease duration were both factors that increased the risk of ICD [58]. As disease 
392 
duration advances, the dopaminergic degeneration spread to brain areas that were 
393 
spared in the early stages of the disease, such as prefrontal cortex [59]. The 
394 
progressive involvement of brain areas during PD progression may have two 
395 
consequences. The first is a dysregulation of brain regions involved in the top-down 
396 
mechanisms of cognitive control of behavior [60]. The second is the need to increase 
397 
DRT dosage to compensate motor symptoms and the consequent overstimulation of 
398 
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less damaged brain areas. However, the relationship between ICD and DRT dosage is 
399 
not well established; some studies report no difference between DRT doses and ICD 
400 
[18, 25, 61, 62], with others reporting an association between ICD and dopamine 
401 
agonists doses [63–68]. In this meta-analysis we lacked the power for conducting 
402 
moderator analysis for disease duration, total LEDD, LD LEDD, and DA LEDD in 
403 
reward-related decision-making and set-shifting leaving this question answered..  
404 
Our data may help reconcile the debate whether ICD in PD is associated with frontal 
405 
lobe dysfunction [69–72]. The discrepancy between previous reports is likely due to 
406 
differences in the tasks and the underlying executive function subdomains 
407 
investigated. Our data indicate that some frontal tasks and related subdomains may 
408 
not be affected by ICD. Therefore, neuropsychological evaluation of ICD+ patients 
409 
should include a broad range of executive function tasks, encompassing both reward-
410 
related decision-making and set-shifting, and not be limited to a general frontal 
411 
screening test, such as the Frontal Assessment Battery.. 
412 
The profile of executive dysfunction we found confirms the conclusions of a previous 
413 
meta-analysis [33] that also reported reduced abstraction/concept formation and 
414 
visuospatial abilities in ICD+. The discrepancy between the two meta-analyses can be 
415 
ascribed to our inclusion of two reports [18,50] not available at the time of the former 
416 
one, and by our stricter exclusion criteria. We excluded four studies included by 
417 
Santangelo et al [7,14,58,59], because of a) patients with hypersexuality and 
418 
compulsive shopping included the ICD- group [7], b) dementia not excluded [14], and 
419 
c) patients screened for pathological gambling [73] or punding [74] only, thereby the 
420 
presence of other ICDs in the ICD- group could not be ruled out. 
421 
Our secondary aim was to explore affective and motivational outcomes associated 
422 
with ICD, as evidence indicates a role for dopamine dysregulation in the 
423 
pathophysiology of impulsivity, apathy, and anhedonia in pathological gambling, 
424 
drug addiction, and ICD+ [75–77]. We found increased rates of self-reported 
425 
depression, anxiety, anhedonia, and impulsivity, but not apathy in ICD+ compared to 
426 
ICD-. 
427 
Impulsivity and apathy have been suggested to represent opposite ends of a 
428 
dopaminergic continuum, where the former and the latter are associated with hyper 
429 
and hypodopaminergic state, respectively [75]. According to this view, DRT 
430 
mesocorticolimbic overstimulation increases impulsivity that, in turn, may enhance 
431 
reward-related behavior that, over time, may become addictive in nature [78]. The 
432 
association between ICD+ and impulsivity but not apathy in our meta-analysis is 
433 
consistent with this model and the evidence that the D2 dopamine agonist 
434 
pramipexole improves apathy in PD patients without ICD [79] but also increases 
435 
impulsivity [1]. 
436 
Anhedonia is defined as the decreased ability to experience pleasure from positive 
437 
stimuli [80]. Pramipexole may reduced anhedonia in ICD-, suggesting its 
438 
hypodopaminergic nature [81]. 
439 
The co-occurrence of hypodopaminergic anhedonia with hyperdopaminergic ICD is 
440 
surprising. One possible explanation is that ICD+ patients may have decreased ability 
441 
to experience pleasure when not engaged in ICD. This hypothesis is supported by the 
442 
evidence that people addicted to alcohol or drugs experience anhedonia during 
443 
withdrawal syndrome, a feature that may facilitate relapse [82]. However, the 
444 
relationship between anhedonia and dopaminergic states is not so straightforward and 
445 
anhedonia is also recognized as one of the overlapping symptoms between apathy and 
446 
depression [83]. The association with anhedonia may be confounded by the presence 
447 
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of depression, which in some cases might be serotoninergically mediated [84]. 
448 
However, there are only two studies and further investigation is needed. 
449 
The pathophysiology of depression and anxiety in PD is likely to be multifactorial 
450 
including reaction to disease diagnosis and anxiety about its future course. Depression 
451 
and anxiety are present in the premorbid PD stage [85], therefore suggesting they may 
452 
represent a core feature of PD. In our meta-analysis depression and anxiety levels 
453 
were higher in ICD+ compared to ICD-. ICD may have a negative impact on the 
454 
quality of life [21,25], and in turn increase depression and anxiety levels. Also, as the 
455 
mesocorticolimbic pathways dysfunction may be involved in depression, anxiety and 
456 
ICD, they might co-occur as epiphenomena of shared neural correlates [40].  
457 
The main limitation of this meta-analysis is the small number of studies, most of 458 
which with small samples that might have contributed to high heterogeneity for some 459 
of the outcomes explored. This consideration could be reflected in the sensitivity 460 
analysis data for long-term visuospatial memory, working memory, attention, 461 
inhibition, reward-related decision-making, apathy, and it suggests caution in the 462 
interpretation of the results for these outcomes. Moreover, the inclusion in the same 463 
domains of tasks that might involve different cognitive processes could have 464 
contributed to the high heterogeneity and the low stability of some results. However, 465 
considering the single cognitive task would have resulted in a reduction of the power, 466 
because of the low number of studies using the same tasks. Unfortunately, we were 467 
not able to perform separate analyses for dopamine agonists and levodopa, as the 468 
majority of the studies included patients who were under both types of DRT. Due to 469 
the small number of studies, moderator analysis for levodopa and dopamine agonist 470 
LEDD was performed for depression only, which showed no effect. This is not 471 
surprising, as in the larger study published so far, ICDs were found to be associated 472 
either with dopamine agonists or, to a lesser extent, with levodopa [1]. These data are 473 
in keeping with the notion that both levodopa and dopamine agonists can interfere 474 
with the phasic and tonic activity of dopaminergic neurons [86] that, by facilitating 475 
neuroadaptive changes in dopaminergic system functioning, may predispose to ICD. 476 
Another limitation is the inclusion of cross-sectional studies that impede the 477 
exploration of the direction of the cause-effect relationship between cognitive, 478 
affective and motivational outcomes and ICD; therefore multi-center and longitudinal 479 
studies are needed. Moreover, even if we excluded studies focusing on punding and 480 
dopamine dysregulation syndrome only, these conditions were present in many 481 
studies, and probably contributed to high heterogeneity for some outcomes. 482 
Furthermore, 23/25 studies did not mention assessors to be blind to the ICD status and 483 
this might have affected tools administration and scoring. Future studies should be 484 
conducted following blinding procedures. Finally, QUIP, a validated screening 485 
instrument with high sensitivity (94%) but low specificity (72%) to ICD in PD [87] 486 
was used in two studies [18,25], possibly leading to false positive and/or subclinical 487 
ICD inclusion. Still unanswered questions include whether set-shifting and reward-488 
related decision-making abnormalities in PD patients with ICD reflect structural and 489 
functional mesocorticolimbic changes due to acute or chronic DRT effects, or 490 
whether they can revert following ICD treatment and remission. Future studies should 491 
address these points, since better understanding ICD pathophysiology may help 492 
tailoring treatment of ICD+. 493 
 494 
ABBREVIATIONS 495 
DBS, deep brain stimulation; DRT, dopamine replacement treatment; H&Y, Hoehn 496 
and Yahr scale; ICD, impulse control disorder; LEDD, levodopa equivalent daily 497 
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dose; PD, Parkinson’s disease; QUIP, Questionnaire for Impulsive-Compulsive 498 
Disorders in Parkinson's Disease; SDM, standardized mean difference; STN-DBS, 499 
sub thalamic nucleus deep brain stimulation; UPRDS, Unified Parkinson’s Disease 500 
Rating Scale. 501 
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Figure 1. PRISMA diagram of the study. DRT: dopaminergic replacement treatment; 760 
ICD: impulse control disorder; ICD+: PD patients with ICD; ICD-: PD patients without 761 
ICD; PD: Parkinson’s disease. 762 
 763 
Figure 2. Forest plots for memory. Here are reported forest plots for short-term (verbal, 764 
panel A; visuospatial, panel B) and long-term (verbal, panel C; visuospatial, panel D) 765 
memory outcomes. Standardized mean difference represents Hedges’s g effect size. The 766 
size of the square indicates the weight of the study. The horizontal line represents the 767 
95% confidence interval. The diamond represents the pooled effect size. Negative effect 768 
sizes indicate worse performance in PD patients with ICD (ICD+) in comparison to 769 
those without ICD (ICD-). ICD: impulse control disorder; PD: Parkinson’s disease. 770 
 771 
Figure 3. Forest plots for working memory and attention. Standardized mean difference 772 
represents Hedges’s g effect size. The size of the square indicates the weight of the 773 
study. The horizontal line represents the 95% confidence interval. The diamond 774 
represents the pooled effect size. Negative effect sizes indicate worse performance in 775 
PD patients with ICD (ICD+) in comparison to those without ICD (ICD-). ICD: impulse 776 
control disorder; PD: Parkinson’s disease. 777 
 778 
Figure 4. Forest plots for executive functions set-shifting and concept formation. Here 779 
are reported forest plots for set-shifting (panel A), and concept formation (reasoning, 780 
panel B; sort and shift, panel C). 781 
 782 
Figure 5. Forest plots for executive functions inhibition, cognitive flexibility, and 783 
reward-related decision-making. Here are reported forest plots for inhibition (panel A), 784 
cognitive flexibility (panel B), and reward-related decision-making (panel C). 785 
Standardized mean difference represents Hedges’s g effect size. The size of the square 786 
indicates the weight of the study. The horizontal line represents the 95% confidence 787 
interval. The diamond represents the pooled effect size. Negative effect sizes indicate 788 
worse performance in PD patients with ICD (ICD+) in comparison to those without 789 
ICD (ICD-). ICD: impulse control disorder; PD: Parkinson’s disease. 790 
 791 
Figure 6. Forest plots for visuospatial abilities and language. Standardized mean 792 
difference represents Hedges’s g effect size. The size of the square indicates the weight 793 
of the study. The horizontal line represents the 95% confidence interval. The diamond 794 
represents the pooled effect size. Negative effect sizes indicate worse performance in 795 
PD patients with ICD (ICD+) in comparison to those without ICD (ICD-). ICD: impulse 796 
control disorder; PD: Parkinson’s disease. 797 
 798 
Figure 7. Forest plots for affective and motivational outcomes. Here are reported forest 799 
plots for depression (panel A), anxiety (panel B), anhedonia (panel C; reasoning, panel 800 
D), apathy (panel E), and impulsivity (panel F). Standardized mean difference 801 
represents Hedges’s g effect size. The size of the square indicates the weight of the 802 
study. The horizontal line represents the 95% confidence interval. The diamond 803 
represents the pooled effect size. Negative effect sizes indicate worse performance in 804 
PD patients with ICD (ICD+) in comparison to those without ICD (ICD-). ICD: impulse 805 
control disorder; PD: Parkinson’s disease. 806 
 807 
Figure 8. Funnel plots for cognitive, affective and motivational outcomes. Here are 808 
reported funnel plots for short-term verbal memory (panel A), inhibition (panel B), 809 
  19 
phonological fluency (panel C), depression (panel D), and anxiety (panel E). There is no 810 
evidence to suggest publication bias. 811 
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Table 1. Characteristics of the studies included in the meta-analysis 812 
Ref Pts (males) Age (y)* PD onset (y)* PD duration (y)* Education (y)* H&Y UPDRS-III (ON)* Depression† Antidepressant 
(N) 
Bentivoglio et 
al[17] 
ICD+: 17 (14) 
ICD-: 17 (11) 
ICD+: 62.0 (10.1) 
ICD-: 63.9 (9.2) 
NR ICD+: 6.9 (3.8) 
ICD-: 7.3 (4.4) 
ICD+: 8.7 (3.7) 
ICD-: 10.2 (4.4) 
ICD+: 2.0 (0.8) 
ICD-: 2.3 (0.5) 
ICD+: 23.8 (11.0) 
ICD-: 22.5 (6.9) 
NO ICD+: 2 
ICD-: 4 
Biundo et al[3] ICD+: 33 (18) 
ICD-: 24 (17) 
ICD+: 61.3 (10.2) 
ICD-: 70.4 (6.8) 
ICD+: 53.2 (10.6) 
ICD-: 60.5 (10.0) 
ICD+: 8.8 (4.8) 
ICD-: 8.9 (5.4) 
ICD+: 11.8 (3.9) 
ICD-: 10.4 (4.8) 
NR ICD+: 30.2 (13.2) 
ICD-: 32.3 (12.8) 
NO NR 
Biundo et al[4] ICD+:58 (38) 
ICD-:52 (32) 
ICD+: 60.3 (9.3) 
ICD-: 63.1 (10.2) 
ICD+: 50.1 (12.1) 
ICD-: 54.7 (11.6) 
ICD+: 9.0 (5.5) 
ICD-: 8.0 (5.7) 
ICD+: 10.9 (4.3) 
ICD-: 11.3 (4.7) 
ICD+: 2.4 (0.7) 
ICD-: 2.3 (0.7) 
ICD+: 26.7 (16.5) 
ICD-: 28.5 (12.3) 
NO NR 
Cera et al[16] ICD+:9 (6) 
PG:10 (7) 
ICD-:14 (7) 
ICD+: 59.3 (6.8) 
PG: 60.6 (6.8) 
ICD-: 59.0 (9.5) 
NR ICD+: 29.0 (8.5)‡ 
PG: 28.2 (12.3) 
ICD-: 27.2 (8.4) 
ICD+: 10.3 (3.2) 
PG: 11.7 (2.6) 
ICD-: 11.7(1.9) 
ICD+: 1.7 (0.3) 
PG: 1.9 (0.2) 
ICD-: 1.7 (0.0) 
ICD+: 21.4 (4.2) 
PG: 20.5 (6.8) 
ICD-: 21.6 (6.9) 
NO NR 
Cilia et al[30] ICD+: 11 (10) 
ICD-: 40 (27) 
ICD+: 57.4 (5.8) 
ICD-: 55 (7) 
ICD+: 49.5 (4.7) 
ICD-: 46.4 (7.2) 
ICD+: 8.4 (3.4) 
ICD-: 8.4 (5.1) 
NR 
NR 
ICD+: 2.1 (0.6) 
ICD-: 2.3 (0.8) 
ICD+: 18.0 (11.0) 
ICD-: 19.1 (8.5) 
YES NO 
Claassen et al[31] ICD+: 12 (8) 
ICD-:12 (6) 
ICD+: 59.4 (5.5) 
ICD-: 60.8 (7.2) 
NR ICD+: 6.5 (4.7) 
ICD-: 6.1 (3.8) 
ICD+: 17.1 (2.7) 
ICD-: 16.3 (2.8) 
NR ICD+: 15.9 (6.6) 
ICD-: 15.7 (8.3) 
YES NO 
Djamshidian et 
al[8] 
ICD+:18 (13) 
ICD-:12 (9) 
ICD+: 55 (2.1) 
ICD-: 63.6 (2.2) 
ICD+: 43.9 (2.1) 
ICD-: 50.9 (2.2) 
ICD+: 10.9 (1.2) 
ICD-: 12.7 (2.1) 
ICD+: 12.2 (0.9) 
ICD-: 14.2 (1.3) 
NR ICD+: 18.0 (2.2)§ 
ICD-: 13.0 (1.4) 
NO NR 
Djamshidian et 
al[9] 
ICD+: 28 (21) 
ICD-:24 (21) 
ICD+: 54.6 (9.2) 
ICD-: 64.2 (10.1) 
ICD+: 44.5 (8.7) 
ICD-: 52.5 (9.6) 
ICD+: 10.1 (5.5) 
ICD-: 11.7 (7.2) 
ICD+: 13.4 (3.0) 
ICD-: 14.7 (3.6) 
NR ICD+: 15.5 (8.3) 
ICD-: 14.4 (5.8) 
NO ICD+: 4 
ICD-: 2 
Erga et al[18] ICD+: 38 (26) 
ICD-:87 (49) 
ICD+: 67.9 (7.7) 
ICD-: 71.4 (9.8) 
NR ICD+: 7.4 (1.6) 
ICD-: 7.4 (1.9) 
NR ICD+: 2.2 (0.5) 
ICD-: 2.2 (0.6) 
ICD+: 23.8 (10.5) 
ICD-: 22.2 (10.7) 
NO ICD+: 5 
ICD-:11 
Housden et al[11] ICD+: 18 (11) 
ICD-:18 (12) 
ICD+: 62.3 (7.6) 
ICD-: 67.7 (5.5) 
NR ICD+: 13.9 (9.0) 
ICD-: 12.9 (8.3) 
NR ICD+: 2.5 (0.6) 
ICD-: 2.5 (0.7) 
ICD+: 20.0 (6.6) 
ICD-: 21.3 (10.4) 
YES NR 
Joutsa et al[23] ICD+:9 (9) 
ICD-:8 (8) 
ICD+: 59.3 (8.4) 
ICD-: 60.1 (5.9) 
ICD+: 53.1 (8.7) 
ICD-: 55.3 (5.1) 
ICD+: 6.1 (1.8) 
ICD-: 5.1 (2.0) 
NR NR ICD+: 31.7 (4.9) 
ICD-: 30.1 (10.7) 
YES NR 
Leroi et al[21] ICD+: 35 
ICD-:38 
NR NR NR NR NR ICD+: 26.9 (10.0) 
ICD-: 24.1 (10.4) 
NO NR 
Mack et al[19] ICD+: 17 (11) 
ICD-:17 (8) 
ICD+: 61.1 (7.5) 
ICD-:  63.8 (8.5) 
ICD+: 48.1 (5.2) 
ICD-: 53.7 (10.0) 
ICD+: 13.1 (6.9) 
ICD-: 10.2 (5.6) 
NR ICD+: 2.8 (1.0) 
ICD-: 2.4 (1.3) 
ICD+: 36.7 (16.1) 
ICD-: 28.5 (15.2) 
NO YES 
Merola et al[42] ICD+: 8 (8) 
ICD-: 113 (60) 
NR ICD+: 48.2 (9.4) 
ICD-: 46.6 (7.3) 
ICD+: 13.4 (7.8) 
ICD-: 13.1 (4.4) 
NR NR ICD+: 14.3 (6.7) 
ICD-: 15.5 (7.8) 
NO NR 
O’Sullivan et 
al[29] 
ICD+:39 (31) 
ICD-:61 (44) 
ICD+: 59.3 (9.1) 
ICD-: 66.6 (9.5) 
ICD+: 45.8 (10.3) 
ICD-: 55.9 (11.7) 
ICD+: 12.0 (6.0) 
ICD-: 9.6 (7.1) 
NR ICD+: 2.6 (0.5) 
ICD-: 2.2 (0.5) 
ICD+: 16.3 (7.5) 
ICD-: 18.5 (8.8) 
NO NR 
O’Sullivan et 
al[28] 
ICD+: 30 (26) 
ICD-: 62 (46) 
ICD+: 58.9 (8.5) 
ICD-: 66.4 (9.7) 
ICD+: 46.2 (10.1) 
ICD-: 55.8 (12.0) 
ICD+: 11.5 (5.9) 
ICD-: 9.5 (7.0) 
NR ICD+: 3 (2-3)¶ 
ICD-: 2 (2-3) 
NR NO YES  
Pettorruso et al[32] PG: 11 (8) 
ICD+: 23 (18) 
ICD-: 120 (60) 
PG: 64.9 (10.9) 
ICD+: 62.0 (9.1) 
ICD-: 67.7 (9.4) 
PG: 56.6 (10.6) 
ICD+: 53.2 (9) 
ICD-: 60.6 (9.2) 
PG: 8.3 (3.2) 
ICD+: 8.8 (6) 
ICD-: 7.0 (5.4) 
PG: 10 (4.2) 
ICD+: 11.3 (4.4) 
ICD-: 11 (5.2) 
NR PG: 20.4 (12.3) 
ICD+: 18.4 (8.5) 
ICD-: 20.4 (8.4) 
NO NR 
Pineau et al [20] ICD+: 17 (14) 
ICD-: 20 (13) 
ICD+: 55 (37–69)|| 
ICD-: 55 (40-62) 
ICD+: 48 (32–65)|| 
ICD-: 48 (35–55) 
ICD+: 7 (2–10)|| 
ICD-: 5.5 (4–12) 
ICD+: 7 (3–7)|| 
ICD-: 7 (3–7) 
NR ICD+: 7 (0–23)|| 
ICD-: 8.5 (0–34) 
NO NR 
Piray et al[22] ICD+: 16 (14) 
ICD-: 15 (12) 
ICD+: 64.4 (3.3) 
ICD-: 63.3 (4.0) 
NR ICD+: 9.6 (2.5) 
ICD-: 8.9 (3.1) 
NR ICD+: 2.5 (0.5) 
ICD-: 2.4 (0.6) 
ICD+: 19.0 (5.3) 
ICD-: 19.6 (6.4) 
NO NR 
Pontieri et al[27] PG: 21 
ICD+: 36 
ICD-: 98 
PG: 58 (9) 
ICD+: 64 (8) 
ICD-: 66 (9) 
PG: 51 (8) 
ICD+: 57 (10) 
ICD-: 61 (9) 
PG: 8 (5) 
ICD+: 7 (4) 
ICD-: 5 (3) 
PG: 10 (4) 
ICD+: 11 (4) 
ICD-: 10 (4) 
PG: 2.0 (0.5) 
ICD+: 1.9 (0.8) 
ICD-: 1.8 (0.5) 
PG: 21.5 (11.6) 
ICD+: 19.1 (12.7) 
ICD-: 19.0 (11.9) 
NO PG: 4 
ICD+: 7 
ICD-: 26 
Rossi et al[10] ICD+: 7 (6) 
ICD-: 13 (10) 
ICD+: 61.4 (6.9) 
ICD-: 65.1 (3.8) 
ICD+: 52.0 (5.6) 
ICD-: 58.3 (6.9) 
NR ICD+: 13.8 (4.1) 
ICD-: 11.9 (5.5) 
ICD+: 2.2 (0.7) 
ICD-: 2.0 (0.7) 
ICD+: 17.0 (9.1) 
ICD-: 14.7 (6.7) 
NO NR 
Tessitore et al[5] ICD+: 15 (13) 
ICD-: 15 (12) 
ICD+: 62.9 (8.6) 
ICD-: 63.1 (8.0) 
NR ICD+: 5.3 (2.9) 
ICD-: 6.6 (3.9) 
ICD+: 9.8 (5) 
ICD-: 12.9 (8) 
ICD+: 1.3 (0.5) 
ICD-: 1.4 (0.6) 
ICD+: 10.9 (4.5) 
ICD-: 12.1 (4.4) 
NO NO 
Vela et al[25] ICD+: 49 (28) 
ICD-: 35 (23) 
ICD+: 48 (44–52)¶ 
ICD-: 46 (42–52) 
NR ICD+: 7 (3−11)¶ 
ICD-: 3 (1−10) 
NR ICD+: 2 (2–2)¶ 
ICD-: 2 (1–2) 
ICD+: 16(10−22)¶ 
ICD-: 17 (11–24) 
NO NO 
Vitale et al [6]  HS: 13 (13) 
M-ICD: 10 (9) 
ICD-: 14  
HS: 68.7 (5.4) 
M-ICD: 62.2 (7.5) 
ICD-: 61.3 (8.2) 
HS: 59.5 (5.6) 
M-ICD: 55.5 (5.3) 
ICD-: 53.2 (9.1) 
HS: 8.5 (3.9) 
M-ICD: 8.1 (4.5) 
ICD-: 7.6 (4.4) 
HS: 9.5 (5) 
M-ICD: 8.2 (2.8) 
ICD-: 13 (4) 
HS: 1.8 (0.5) 
M-ICD: 1.5 (0.7) 
ICD-: 1.8 (0.8) 
HS: 15.1 (6.5) 
M-ICD: 13 (7.1) 
ICD-: 11.7 (6) 
NO HS: 1 
M-ICD: 2 
ICD-: 0 
Wu et al[26] S-ICD: 7 S-ICD: 62.3 (3.9)  S-ICD: 51.7 (4.0) S-ICD: 10.6 (2.0) NR NR NR NO NR 
  21 
M-ICD: 10 
ICD-: 9 
M-ICD: 58.1 (2.8) 
ICD-: 60.2 (3.2) 
M-ICD: 43.8 (3.4) 
ICD-: 50.3 (3.4) 
M-ICD: 14.3 (11.2) 
ICD-: 9.9 (2.1) 
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Table 1 (continued). Characteristics of the studies included in the meta-analysis 814 
 815 
Ref Antipsychotic: 
N 
LEDD (mg) Outcomes 
 
ICD 
Total LEDD* LD-LEDD* DA-LEDD* Diagnosis** Type: N 
Bentivoglio et 
al[17] 
ICD+: 3 ICD+: 606.1 (319.2) 
ICD-: 616.2 (367.8) 
ICD+: 539 (264.3) 
ICD-: 455.7 (299.0) 
ICD+: 172.9 (112.2) 
ICD-: 192.5 (88.5) 
Digit span forward; CBTT; Immediate visual 
memory; RAVLT; Digit span backward; 
Double barrage; FAB; MWCST; RCPM; 
Stroop; Fluency (semantic, phonological); 
IGT; Apraxia (ideomotor, orofacial, 
constructional); Oral confrontation naming 
(nouns, verbs); HAM-D; HAM-A; BIS-11 
Clinical interview 
(DSM-IV)  
HS: 8; CS: 2; PG: 10; BE: 
6; M-ICD: 7 
Biundo et 
al[3] 
NR ICD+: 556.8 (304.6) 
ICD-: 497.4 (341.2) 
NR ICD+: 186.5 (149.3) 
ICD-: 165.8 (108.8) 
Digit span forward; CBTT; RAVLT; ROCF 
(copy, delayed); Digit span backward; TMT 
A; FAB; TMT B; RCPM; Similarities for 
abstract verbal reasoning; Stroop; Fluency 
(semantic, phonological); BDI 
MIDI; DSM-IV-
TR; interview 
(caregivers); 
additional clinical 
interview 
HS: 11; CS: 9; PG: 1; 
punding: 
2; M-ICD: 12 
Biundo et 
al[4] 
NR ICD+: 923.1 (474.1) 
ICD-: 722.6 (498.5) 
NR ICD+: 163.7 (111.3) 
ICD-: 148.9 (105.0) 
Digit span forward; CBTT; Prose 
(immediate, delayed); ROCF; Digit ordering 
test; TMT-A; TMT B; Stroop; Fluency 
(semantic, phonological); Naming; VOSP; 
Clock drawing test; BDI 
QUIP-RS; MIDI; 
clinical interview 
(patient and 
carergiver) 
HS: 6; CS: 7; PG: 2; 
hoarding: 2; impulsive 
aggression: 1; M-ICD: 40 
Cera et al[16] NO ICD+: 283.3 (132.9) 
PG: 294.5 (123.1) 
ICD-: 307 (96.3) 
NR NR Stroop test; Emotional Stroop test; Monetary 
risk tasking task 
DSM-IV, QUIP-
RS, SOGS 
PG:10; M-ICD: 9 
Cilia et al[30] NO ICD+: 811.8 (229.0) 
ICD-: 877.3 (289.3) 
NR ICD+: 289.1 (57.5) 
ICD-: 340.1 (157.2) 
FAB; RPM; GDS Diagnostic criteria; 
SOGS 
PG:1; PG+HS: 5; PG+BE: 
2; PG+CS: 2; PG+IA: 1 
Claassen et 
al[31] 
NO ICD+: 618.7 (361.9) 
ICD-: 520.3 (314.9) 
ICD+: 408.2 (349.6) 
ICD-: 319.7 (318.9) 
ICD+: 293.8 (167.4) 
ICD-: 200.6 (116.8) 
Stop signal task; CESD QUIP; clinical 
interview 
HS: 5; CS: 5; BE: 6; 
hobbism: 9 
Djamshidian 
et al[8] 
NR ICD+: 971 (183)§ 
ICD-: 732 (203) 
ICD+: 752 (109)§ 
ICD-: 604 (73) 
NR Digit span backward; Risk Task; Learning 
task. 
Diagnostic criteria PG: 10; HS:9; CS: 5; BE: 
7; DDS: 6; punding: 2; 
kleptomania: 1 
Djamshidian 
et al[9] 
NR ICD+: 832 (425) 
ICD-: 821 (400) 
NR NR Stroop Diagnostic criteria PG: 11; HS: 13; CS: 8; 
punding:4; kleptomania:1 
Erga et al[18] NR ICD+: 730.6 (343.3) 
ICD-: 658.4 (275.9) 
ICD+: 505.2 (279.1) 
ICD-: 408.7 (266.7) 
ICD+: 293.7 (132.4) 
ICD-: 289.5 (150.0) 
CLVT-II; Stroop; Fluency (phonological); 
VOSP; MADRS 
QUIP M-ICD: 36 (PG: 2; HS: 7; 
CS:6; BE:14; punding:12; 
hobbyism:13; DDS: 3) 
Housden et 
al[11] 
NR ICD+: 891.5 (432.1) 
ICD-: 804.8 (358.5) 
ICD+: 643.5 (254.1) 
ICD-: 634.2 (301.7) 
ICD+: 248 (301.3) 
ICD-: 170.5 (159.3) 
Digit span forward; Digit span backward; 
KDDT; WTAR; SAT; BDI; STAI-state 
Structured 
interview 
(diagnostic criteria) 
PG:9; BE: 9; HS: 7; CS: 6; 
DDS: 4; punding: 8 
Joutsa et 
al[23] 
NR ICD+: 628 (186) 
ICD-: 762 (269) 
NR ICD+: 173 (80) 
ICD-: 216 (67) 
KDDT Diagnostic criteria PG: 5; HS: 4; BE: 1 
Leroi et al[21] NR NR NR NR n-back; Fluency (phonological); HADS-D; 
HADS-A; AES-C; BIS-11  
Diagnostic criteria; 
SOGS 
PG: 12; HS: 9; CS: 5; BE: 
3; DDS: 3; punding: 3 
Mack et al[19] NR ICD+: 1,677.9 (893.0) 
ICD-: 1,269.3 (560.7) 
NR NR Digit span; HVLT-R; TMT-A; TMT-B; 
Fluency (semantic, phonological); NART; 
BDI 
Semistructured 
interview 
(diagnostic criteria) 
 
 
NR 
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Table 1 (continued). Characteristics of the studies included in the meta-analysis 820 
Ref Antipsychotic: N LEDD (mg) Outcomes 
 
ICD 
Total LEDD* LD-LEDD* DA-LEDD* Diagnosisg Type: N 
Merola et 
al[42] 
NR ICD+: 1576.4 (397.6) 
ICD-: 1216.2 (403.0) 
NR ICD+: 344.4 (314.5) 
ICD-: 297.2 (235.3) 
Digit span forward; Bi-syllabic words 
repetition test; CBTT; Paired associate 
learning; TMT-A; Digit cancellation test; 
FAB; TMT-B; MWCST; RCPM; Fluency 
(semantic, phonological); BDI; STAI-state; 
AES-C 
Clinical interview 
(diagnostic criteria) 
PG, HS, CS, punding, DDS 
O’Sullivan et 
al[29] 
NR ICD+: 927 (658) 
ICD-: 742 (477) 
ICD+: 684 (512) 
ICD-: 588 (418) 
ICD+: 259 (472) 
ICD-: 139 (200) 
HADS-D; HADS-A; BSCS; Impulse buying 
tendency;  
Semistructured 
interview 
(diagnostic criteria) 
Punding: 20; BE: 14; HS: 12; PG: 
11; CS: 11; DDS: 11 
O’Sullivan et 
al[28] 
NR ICD+: 981 (651) 
ICD-: 645 (443) 
ICD+: 701 (508) 
ICD-: 543 (399) 
ICD+: 201 (0-284)¶ 
ICD-: 0 (0-201) 
HADS-D; HADS-A Semistructured 
interview 
(diagnostic criteria) 
HS: 12; PG: 11; CS: 8; BE: 8; 
punding: 15 
Pettorruso et 
al[32] 
NR PG: 712 (373) 
ICD+: 654 (380) 
ICD-: 575 (420) 
PG: 592 (404) 
ICD+: 458 (376) 
ICD-: 445 (386) 
PG: 120 (99) 
ICD+: 196 (113) 
ICD-: 130 (112) 
FAB; HAM-D; HAM-A; SHAPS; BIS-11  Interview 
(diagnostic criteria) 
S-ICD: 24; M-ICD: 10 (PG: 11; 
HS: 20; BE: 9; CS: 5) 
Pineau et al 
[20] 
NR ICD+: 897.5 (299.9–
1247.3)|| 
ICD-: 1049.9 (527.1–
1549.8) 
NR ICD+: 299.9 (77–718.0)|| 
ICD-: 340.2 (66.7–700.0) 
Conner's performance test; TMT B-A; 
MWCST; Fluency (phonological); IGT; 
MADRS; Starkstein apathy scale; BIS-11  
Semistructured 
interview; ASBPD 
 
PG: 6; HS: 1; CS: 2; CE: 2; M-
ICD: 6 
Piray et al[22] NR NR NR NR Digit span forward; Digit span backward; 
Probabilistic reward learning task; NAART; 
BDI; BIS-11 
Interview S-ICD: 4; M-ICD: 12 (CS: 10; 
HS: 9; PG: 6; BE: 4) 
Pontieri et 
al[27] 
PG: 2 
ICD+: 3 
ICD-:4 
PG: 794 (603) 
ICD+: 704 (509) 
ICD-: 416 (304) 
PG: 487 (625) 
ICD+: 388 (278) 
ICD-: 251 (279) 
PG: 307 (275) 
ICD+: 316 (374) 
ICD-: 166 (197) 
RAVLT (immediate, delayed); ROCF 
(immediate, delayed); MWCST; Stroop; 
Fluency (semantic, phonological); HAM-D; 
HAM-A; SHAPS; Starkstein apathy scale 
Diagnostic criteria; 
QUIP 
PG: 21 (PG only:10; PG and 
other ICD:11); HS:16; CS:3; 
BE:10;M-ICD: 7 
Rossi et al[10] NR ICD+: 935.9 (548.6) 
ICD-: 698.2 (474.6) 
NR ICD+: 201.9 (78.0) 
ICD-: 223.9 (136.8) 
FAB; MWCST; Go/No-Go; Stroop; IGT; 
Game of dice; Investment task; Social 
cognition; Reversal and extinction learning; 
MADRS 
Interview 
(diagnostic 
criteria); MIDI; 
SOGS; 
PG: 7; HS: 2; CS: 2; DDS:2 
Tessitore et 
al[5] 
NO ICD+: 477.3 (222.9) 
ICD-: 532.1 (207.2) 
NR ICD+: 243.3 (82.1) 
ICD-: 243.3 (90.2) 
CBTT; RAVLT (immediate, delayed); 
Attentional matrices; TMT-B; WCST; 
RCPM; Stroop; Fluency (semantic, 
phonological); ROCF; HAM-D; HADS 
MIDI HS:13; BE:8; PG: 1 
Vela et al[25] NO ICD+: 543 (248–1039)¶ 
ICD-: 460 (133–700) 
ICD+: 300 (0–675)¶ 
ICD-: 300 (0–600) 
ICD+: 210 (168–308)¶ 
ICD-: 180 (0−300) 
BDI QUIP PG: 9; HS: 20; CS: 13; BE: 17; 
hobbyism: 25; punding: 15; 
walkabout: 4 
Vitale et al [6] HS: 2 
M-ICD: 0 
ICD-: 0 
HS: 727.3 (254.3) 
M-ICD: 808.3 (292.2) 
ICD-: 630.3 (311.8) 
NR HS: 200 (130.4) 
M-ICD: 207.1 (159.2) 
ICD-: 267.1 (201.3) 
WCST; ROCF copy; TMT B-A; Attentional 
matrices; Stroop; RAVLT (immediate, 
delayed); HAM-D; HADS-A; HADS-D 
MIDI; clinical 
interview 
HS: 13; M-ICD: 10 
Wu et al[26] NR S-ICD: 782.3 (83.5) 
M-ICD: 724.0 (99.0) 
ICD-: 831.9 (119.2) 
S-ICD: 538.0 (83.4) 
M-ICD: 268.5 (84.9) 
ICD-: 666.3 (129.0) 
S-ICD: 244.3 (51.4) 
M-ICD: 244.0 (55.4) 
ICD-: 165.6 (48.9) 
BDI Semistructured 
interview 
HS: 4; PG: 3; M-ICD: 10 
Legend. AES-C: Apathy evaluation scale by a clinician; ASBPD: Ardouin scale of behaviour in Parkinson's disease; BDI: Beck depression inventory; BE: binge eating; BIS-11: 821 
Barrat impulsiveness scale-11; BSCS: Brief self-control scale CBTT: Corsi’s block-tapping test; CESD: Center for Epidemiological Studies-Depression scale; CLVT-II: 822 
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California verbal learning test II; CS: compulsive shopping; DA: dopamine agonists; DDS: Dopamine dysregulation syndrome; DSB: digit span backward; DSF: digit span 823 
forward; DSM-IV: diagnostic and statistical manual of mental disorders, fourth edition; DSM-IV-TR: diagnostic and statistical manual of mental disorders, fourth edition, text 824 
revision; FAB: frontal assessment battery; GDS: Geriatric depression scale; HADS-A: Hospital anxiety and depression scale – anxiety subscale; HADS-D: Hospital anxiety and 825 
depression scale – depression subscale; HAM-A: Hamilton rating scale for anxiety; HAM-D: Hamilton rating scale for depression; H&Y: Hoehn & Yahr score; HS: hyper-826 
sexuality; HVLT-R: Hopkins verbal learning test revised; IA: internet addiction; ICD: impulse control disorder; ICD+: PD patients with ICD; ICD-: PD patients without ICD; 827 
IGT: Iowa gambling task; KDDT: Kirby delayed discounting questionnaire; LEDD: levodopa equivalent daily dosage (mg); LD: levodopa; MADRS: Montgomery-Asberg 828 
depression rating scale; M-ICD: multiple ICD; MIDI: Minnesota impulsive disorder interview; MMSE: mini mental state examination; MWCST: Modified Wisconsin card 829 
sorting test; N: number of patients; NAART: North American adult reading test; NART: The National adult reading test; NR: not reported. PD: Parkinson’s disease; PG: 830 
pathological gambling; Pts: patients; QUIP: questionnaire for impulsive-compulsive disorders in Parkinson’s disease; QUIP-RS: questionnaire for impulsive-compulsive disorders 831 
in Parkinson’s disease rating scale; RAVLT: Rey’s auditory verbal learning test; RCPM: Raven’s coloured progressive matrices; Ref: reference number; ROCF: Rey-Osterrieth 832 
complex figure test; RPM: Raven’s progressive matrices; SAT: salience attribution test; SHAPS: Snaith-Hamilton pleasure scale; S-ICD: single ICD; SOGS: South oaks 833 
gambling screen; STAI-state: state-trait anxiety inventory; TMT-A: trail making test part A; TMT-B: trial making test part B; UPDRS-III: unified Parkinson’s disease rating scale 834 
part III (motor subscale) score; VOSP: visual object and space perception battery; WCST: Wisconsin card sorting test; WTAR: Wechsler test of adult reading; y: years. *Mean 835 
(SD) unless otherwise stated. †Depression as an exclusion factor. ‡Data reported in months. §Mean (SEM). ¶Median (interquartile range). ||Median (lower–upper quartile). 836 
**Questionnaire or method use to screen and/or diagnose ICD. 837 
 838 
 839 
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Table 2. Cognitive subdomains and tasks used in the studies included in the meta-analysis 840 
Cognitive subdomain Cognitive tasks References 
Short-term verbal memory CVLT-II immediate  Erga et al., 2017 [18] 
Digit Span Forward Bentivoglio et al., 2013 [17]; Biundo et al., 2011 [3]; Biundo et al., 2015 [4]; Housden et al., 2010 [11]; Merola et al., 2017 [42]; 
Piray et al., 2014 [22] 
RAVLT - immediate Pontieri et al., 2015 [27]; Tessitore et al., 2016 [5]; Vitale et al., 2011 [6] 
Short-term visuospatial 
memory  
CBTT Bentivoglio et al., 2013 [17]; Biundo et al., 2011 [3]; Biundo et al., 2015 [4]; Merola et al., 2017 [42]; Tessitore et al., 2016 [5] 
Long-term verbal memory  CVLT-II delayed  
HVLT-R delayed  
Paired associate learning 
Prose Memory  
Erga et al., 2017 [18] 
Mack et al., 2013 [19] 
Merola et al., 2017 [42]  
Biundo et al., 2015 [4] 
RAVLT- delayed Bentivoglio et al., 2013 [17]; Biundo et al., 2011 [3]; Pontieri et al., 2015 [27]; Tessitore et al., 2016 [5]; Vitale et al., 2011 [6] 
Long-term visuospatial 
memory  
ROCF – delayed Biundo et al., 2011 [3]; Biundo et al., 2015 [4]; Pontieri et al., 2015 [27] 
Working memory Digit Ordering Test Biundo  et al., 2015 [4] 
Digit Span Backward Bentivoglio et al., 2013 [17]; Biundo et al., 2011 [3]; Djamshidian et al., 2010 [8]; Housden et al., 2010 [11]; Piray et al., 2014 [22] 
n-Back Leroi et al., 2011 [21] 
Attention Attentive Matrices Tessitore et al., 2016 [5]; Vitale et al., 2011 [6] 
Conner’s Performance Test Pineau et al., 2016 [20] 
Double barrage – accuracy Bentivoglio et al., 2013 [17] 
TMT-A Biundo et al., 2011 [3]; Biundo et al., 2015 [4]; Mack et al., 2013 [19]; Merola et al., 2017 [42] 
Set-shifting TMT-B Biundo et al., 2011 [3]; Biundo et al., 2015 [4]; Mack et al., 2013 [19]; Merola et al., 2017 [42]; Tessitore et al., 2016 [5] 
TMT- B-A Pineau et al., 2016 [20]; Vitale et al., 2011 [6] 
Concept formation (sort 
and shift) 
MWCST – categories Bentivoglio et al., 2013 [17]; Merola et al., 2017 [42]; Pineau et al., 2016 [20]; Pontieri et al., 2015 [27]; Rossi et al., 2010 [10] 
WCST – global score Tessitore et al., 2016 [5]; Vitale et al., 2011 [6] 
Concept formation 
(reasoning) 
RCPM 
RPM 
Bentivoglio et al., 2013 [17]; Biundo et al., 2011 [3]; Merola et al., 2017 [42]; Tessitore et al., 2016 [5] 
Cilia et al., 2008 [30] 
Inhibition Go/no-Go – errors Rossi et al., 2010 [10] 
Stop Signal Task Claassen et al., 2015 [31] 
Stroop errors Bentivoglio et al., 2013 [17]; Biundo et al., 2011 [3]; Biundo et al., 2015 [4]; Djamshidian et al., 2011 [9]; Vitale et al., 2011 [6] 
Stroop time Cera et al., 2014 [16]; Erga et al., 2017 [18]; Pontieri et al., 2015 [27]; Tessitore et al., 2016 [5] 
Cognitive flexibility Phonological Fluency  Bentivoglio et al., 2013 [17]; Biundo et al., 2011 [3]; Biundo et al., 2015 [4]; Erga et al., 2017 [18]; Leroi et al., 2011 [21]; Mack et 
al., 2013 [19]; Merola et al., 2017 [42]; Pineau et al., 2016 [20]; Pontieri et al., 2015 [27]; Tessitore et al., 2016 [5] 
Reward-related decision-
making 
IGT Bentivoglio et al., 2013 [17]; Pineau et al., 2016 [20]; Rossi et al., 2010 [10] 
KDDQ Housden et al., 2010 [11]; Joutsa et al., 2015 [23] 
Monetary risk taking Cera et al., 2014 [16] 
Probabilistic Reward Piray et al., 2014 [22] 
Risk Task Djamshidian et al., 2010 [8] 
Visuospatial abilities Constructional apraxia Bentivoglio et al., 2013 [17] 
ROCF – copy Biundo et al., 2011 [3]; Biundo et al., 2015 [4]; Pontieri et al., 2015 [27]; Tessitore et al., 2016 [5]; Vitale et al., 2011 [6] 
VOSP - silhuette Erga et al., 2017 [18] 
Language Naming Biundo et al., 2015 [4] 
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Oral Verbal Naming Bentivoglio et al., 2013 [17] 
Affective and 
Motivational 
Self-report measures References 
Depression BDI Biundo et al., 2011 [3]; Biundo  et al., 2015 [4]; Housden et al., 2010 [11]; Mack et al., 2013 [19]; Merola et al., 2017 [42]; Piray et 
al., 2014 [22]; Vela et al., 2016 [25]; Wu et al., 2015 [26] 
CESD Claassen et al., 2015 [31] 
GDS Cilia et al., 2008 [30] 
HADS-D Leroi et al., 2011 [21]; O’Sullivan et al., 2010 [29]; O’Sullivan et al., 2011 [28]; Vitale et al., 2011 [6] 
HAM-D Bentivoglio et al., 2013 [17]; Pettorruso et al., 2014 [32]; Pontieri et al., 2015 [27]; Tessitore et al., 2016 [5] 
MADRS Erga et al., 2017 [18]; Pineau et al., 2016 [20]; Rossi et al., 2010 [10] 
Anxiety HADS-A Leroi et al., 2011 [21]; O’Sullivan et al., 2010 [29]; O’Sullivan et al., 2011 [28]; Tessitore et al., 2016 [5]; Vitale et al., 2011 [6] 
HAM-A Bentivoglio et al., 2013 [17]; Pettorruso et al., 2014 [32]; Pontieri et al., 2015 [27] 
STAI-state Housden et al., 2010 [11]; Merola et al., 2017 [42] 
Anhedonia SHAPS Pettorruso et al., 2014 [32]; Pontieri et al., 2015 [27] 
Apathy AES-C Leroi et al., 2011 [21]; Merola et al., 2017 [42] 
Starkstein Apathy Scale Pineau et al., 2016 [20]; Pontieri et al., 2015 [27] 
Impulsivity BIS-11 Bentivoglio et al., 2013 [17]; Leroi et al., 2011 [21]; Pettorruso et al., 2014 [32]; Pineau et al., 2016 [20]; Piray et al., 2014 [22] 
BSCS O’Sullivan et al., 2010 [29] 
Legend. AES-C: Apathy evaluation scale by a clinician; BDI: Beck depression inventory; BIS-11: Barrat impulsiveness scale-11; BSCS: brief self-control scale; CBTT: Corsi’s 841 
block-tapping test; CVLT-II: California verbal learning test II; CESD: Centre for Epidemiological Studies-Depression scale; GDS: Geriatric depression scale; HADS-A: Hospital 842 
anxiety and depression scale-anxiety subscale; HADS-D: Hospital anxiety and depression scale-depression subscale; HAM-A: Hamilton rating scale for anxiety; HAM-D: 843 
Hamilton rating scale for depression; HVLT-R: Hopkins verbal learning test revised; IGT: Iowa gambling task; KDDQ: Kirby delayed discounting questionnaire; MADRS: 844 
Montgomery-Asberg depression rating scale; MWCST: modified Wisconsin card sorting test; RAVLT: Rey’s auditory verbal learning test; RCPM: Raven’s colored progressive 845 
matrices; ROCF: Rey-Osterrieth complex figure test; RPM: Raven’s progressive matrices; SHAPS: Snaith-Hamilton pleasure scale; STAI-state: state-trait anxiety inventory; 846 
TMT-A: trail making test part A; TMT-B: trail making test part B; VOSP: visual object and space perception battery; WCST: Wisconsin card sorting test.In bold scores that have 847 
been reversed in order to obtain scores with the same meaning (e.g., higher scores better performances). 848 
 849 
 850 
 851 
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Table 3. Results of the meta-analyses 852 
 853 
 854 
 855 
 856 
 857 
 858 
 859 
 860 
 861 
 862 
 863 
 864 
 865 
 866 
 867 
 868 
 869 
 870 
 871 
 872 
 873 
 874 
 875 
 876 
 877 
 878 
 879 
Legend. K: number of studies; N: number of participants; SMD: standardized mean difference; CI: confidence interval. P values below the significance level (p<0.05) are 880 
reported in italics. 881 
 882 
   Random-effect model results  Heterogeneity 
Outcome K N SMD [95% CI] Z p  X2 p I2 
Short-term verbal memory 10 736 -0.25 [-0.66, 0.16] 1.22 0.22  51.26 <0.00001 82% 
Short-term visuospatial memory 5 352 -0.12 [-0.42, 0.17] 0.82 0.41  5.26 0.26 24% 
Long-term verbal memory 9 702 -0.18 [-0.52, 0.16] 1.04 0.30  29.66 0.0002 73% 
Long-term visuospatial memory 3 322 -0.21 [-0.64, 0.21] 0.99 0.32  6.64 0.04 70% 
Working memory 7 371 -0.21 [-0.54, 0.13] 1.19 0.24  14.73 0.02 59% 
Attention 8 460 -0.22 [-0.47, 0.03] 1.73 0.08  9.40 0.23 26% 
Set-shifting 7 426 -0.49 [-0.78, -0.21] 3.37 0.0008  9.32 0.16 36% 
Concept formation (sort and shift) 7 434 -0.15 [-0.48, 0.19] 0.86 0.39  11.56 0.07 48% 
Concept formation (reasoning) 5 293 -0.21 [-0.56, 0.14] 1.16 0.25  5.66 0.23 29% 
Inhibition 11 677 -0.23 [-0.59, 0.12] 1.27 0.20  44.95 <0.00001 78% 
Cognitive flexibility 10 776 -0.02 [-0.25, 0.20] 0.19 0.85  16.79 0.05 46% 
Reward-related decision-making 8 238 0.42 [0.02, 0.82] 2.05 0.04  15.50 0.03 55% 
Visuospatial abilities 7 548 -0.30 [-0.69, 0.08] 1.57 0.12  24.86 0.0004 76% 
Language 2 144 -0.35 [-0.87, 0.17] 1.31 0.19  1.96 0.16 49% 
Depression 21 1431 0.35 [0.16, 0.54] 3.54 0.0004  51.42 0.0001 61% 
Anxiety 10 832 0.43 [0.18, 0.68] 3.39 0.0007  21.27 0.01 58% 
Anhedonia 2 309 0.26 [0.01, 0.50] 2.01 0.04  0.01 0.94 0% 
Apathy 4 386 0.42 [-0.04, 0.87] 1.81 0.07  9.09 0.03 67% 
Impulsivity 6 429 0.79 [0.50, 1.09] 5.26 <0.00001  8.89 0.11 44% 
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Table 4. Results of the moderator analysis 883 
 Short-term Verbal Memory Inhibition Cognitive Flexibility Depression Anxiety 
Moderators K β p K β p K β p K β p K β p 
Age 9a -- -- 11 -0.003 0.970 8a -- -- 19 -0.029 0.183 8a -- -- 
Education 8a -- -- 10 -0.050 0.669 6a -- -- 10 -0.055 0.332 6a -- -- 
PD Duration 8a -- -- 10 0.045 0.645 9a -- -- 19 -0.012 0.810 8a -- -- 
H&Y Stage 8a -- -- 8a -- -- 6a -- -- 14 -0.153 0.570 7a -- -- 
UPDRS-III 10 0.073 0.081 11 0.018 0.578 10 -0.005 0.799 19 -0.009 0.557 9a -- -- 
Total LEDD 9a -- -- 10 0.002 0.200 9a -- -- 19 0.000 0.992 9a -- -- 
DA LEDD 9a -- -- 9a -- -- 8a -- -- 18 0.001 0.435 9a -- -- 
LD LEDD 4a -- -- 5a -- -- 3a -- -- 10 0.000 0.749 6a -- -- 
 884 
Legend. PD: Parkinson’s disease; H&Y: Hoehn & Yahr score; UPDRS-III: unified Parkinson’s disease rating scale part III (motor subscale) score; LEDD: levodopa equivalent 885 
daily dosage (mg); DA: dopamine agonist; LD: levodopa; K: number of studies. 886 
anot included in the moderator analysis because k< 887 
